TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from PureTech Health ( (GB:PRTC) ) is now available.
Gallop Oncology, a PureTech Health entity, announced promising results from a Phase 1b trial of LYT-200, a monoclonal antibody for relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The trial showed LYT-200’s favorable safety and efficacy, with a median overall survival of 13.2 months in combination therapy, significantly exceeding the typical survival rate of less than 2.5 months. These results suggest LYT-200’s potential for broader applicability across high-risk mutations and support its advancement to a Phase 2 trial. The findings highlight a potential shift in AML treatment, with LYT-200’s unique mechanism targeting galectin-9, a key oncogenic driver.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £121.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
The overall stock score of 54 reflects a mixed outlook for PureTech Health. The company’s strong liquidity and undervaluation are positive factors, but these are offset by bearish technical indicators and operational risks. The earnings call provided some optimism, but management changes and funding uncertainties remain concerns.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a hub-and-spoke biotherapeutics company focused on transforming scientific innovation into value. The company operates through a capital-efficient R&D model, advancing therapeutic candidates with validated pharmacology to address significant patient needs. PureTech has successfully developed several therapeutic candidates, with three receiving U.S. FDA approval. Gallop Oncology, a wholly-owned entity of PureTech, is dedicated to developing treatments for hematologic malignancies, with its lead candidate LYT-200 targeting galectin-9 to address acute myeloid leukemia (AML).
Average Trading Volume: 758,952
Technical Sentiment Signal: Strong Sell
Current Market Cap: £295.3M
Find detailed analytics on PRTC stock on TipRanks’ Stock Analysis page.